News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
802,340 Results
Type
Article (57376)
Company Profile (396)
Press Release (744547)
Multimedia
Podcasts (183)
Webinars (28)
Section
Business (221123)
Career Advice (2960)
Deals (38319)
Drug Delivery (166)
Drug Development (88217)
Employer Resources (195)
FDA (17844)
Job Trends (16480)
News (376600)
Policy (36712)
Tag
2027 BioCapital Elite (1)
2027 BioMidwest Elite (2)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (2)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (4)
2027 Genetown Standard (4)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (6)
Academia (2985)
Academic (1)
Accelerated approval (54)
Adcomms (38)
Allergies (188)
Alliances (54059)
ALS (227)
Alzheimer's disease (1945)
Antibody-drug conjugate (ADC) (521)
Approvals (18165)
Artificial intelligence (769)
Autoimmune disease (334)
Automation (59)
Bankruptcy (394)
Best Places to Work (12324)
BIOSECURE Act (23)
Biosimilars (242)
Biotechnology (245)
Bladder cancer (208)
Brain cancer (82)
Breast cancer (811)
Cancer (6315)
Cardiovascular disease (540)
Career advice (2519)
Career pathing (51)
CAR-T (361)
CDC (74)
Celiac Disease (3)
Cell therapy (994)
Cervical cancer (51)
Clinical research (76199)
Collaboration (2279)
Company closure (7)
Compensation (1457)
Complete response letters (101)
COVID-19 (3004)
CRISPR (120)
C-suite (1244)
Cystic fibrosis (163)
Data (8352)
Decentralized trials (3)
Denatured (50)
Depression (188)
Dermatology (94)
Diabetes (641)
Diagnostics (7412)
Digital health (59)
Diversity (13)
Diversity, equity & inclusion (47)
Drug discovery (366)
Drug pricing (242)
Drug shortages (38)
Duchenne muscular dystrophy (309)
Earnings (96672)
Editorial (78)
Employer branding (24)
Employer resources (167)
Events (130267)
Executive appointments (1176)
FDA (21772)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (18)
Frontotemporal dementia (35)
Funding (1850)
Gene editing (262)
Generative AI (67)
Gene therapy (811)
GLP-1 (1252)
Government (5336)
Grass and pollen (8)
Guidances (415)
Healthcare (20598)
HIV (89)
Huntington's disease (61)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (106)
Immunology and inflammation (346)
Immuno-oncology (110)
Indications (198)
Infectious disease (3385)
Inflammatory bowel disease (239)
Inflation Reduction Act (15)
Influenza (145)
Intellectual property (307)
Interviews (571)
IPO (17514)
IRA (59)
Job creations (4475)
Job search strategy (2039)
JPM (71)
Kidney cancer (22)
Labor market (110)
Layoffs (660)
Leadership (52)
Legal (9119)
Liver cancer (110)
Longevity (35)
Lung cancer (835)
Lymphoma (448)
Machine learning (63)
Management (65)
Manufacturing (1147)
MASH (220)
Medical device (14761)
Medtech (14898)
Mergers & acquisitions (22081)
Metabolic disorders (1721)
mRNA (246)
Multiple sclerosis (202)
NASH (24)
Neurodegenerative disease (484)
Neuropsychiatric disorders (124)
Neuroscience (3620)
Neurotech (1)
NextGen: Class of 2026 (7241)
Non-profit (4987)
Now hiring (80)
Obesity (829)
Opinion (360)
Ovarian cancer (238)
Pain (279)
Pancreatic cancer (326)
Parkinson's disease (401)
Partnered (34)
Patents (634)
Patient recruitment (725)
Peanut (67)
People (65416)
Pharmaceutical (96)
Pharmacy benefit managers (37)
Phase 1 (23688)
Phase 2 (33375)
Phase 3 (24989)
Pipeline (9311)
Policy (380)
Postmarket research (2998)
Preclinical (10169)
Press Release (71)
Prostate cancer (329)
Psychedelics (67)
Radiopharmaceuticals (358)
Rare diseases (1212)
Real estate (6736)
Recruiting (77)
Regulatory (28151)
Reports (63)
Research institute (2692)
Resumes & cover letters (465)
Rett syndrome (40)
RNA editing (25)
RSV (96)
Schizophrenia (194)
Series A (312)
Series B (226)
Service/supplier (13)
Sickle cell disease (121)
Special edition (32)
Spinal muscular atrophy (184)
Sponsored (51)
Startups (4058)
State (2)
Stomach cancer (21)
Supply chain (138)
Tariffs (104)
The Weekly (130)
Vaccines (1260)
Venture capital (123)
Weight loss (570)
Women's health (133)
Worklife (24)
Date
Today (1)
Last 7 days (640)
Last 30 days (3234)
Last 365 days (31871)
2026 (14474)
2025 (32063)
2024 (37200)
2023 (42096)
2022 (53394)
2021 (58088)
2020 (56908)
2019 (50183)
2018 (38032)
2017 (35168)
2016 (35224)
2015 (41225)
2014 (35449)
2013 (30748)
2012 (32662)
2011 (33234)
2010 (31387)
Location
Africa (984)
Alabama (101)
Alaska (7)
Arizona (370)
Arkansas (16)
Asia (46858)
Australia (8165)
California (13924)
Canada (3907)
China (1492)
Colorado (589)
Connecticut (609)
Delaware (425)
Europe (103960)
Florida (2081)
Georgia (447)
Hawaii (3)
Idaho (67)
Illinois (1151)
India (99)
Indiana (633)
Iowa (24)
Japan (572)
Kansas (137)
Kentucky (53)
Louisiana (46)
Maine (76)
Maryland (1696)
Massachusetts (10094)
Michigan (393)
Minnesota (770)
Mississippi (7)
Missouri (159)
Montana (35)
Nebraska (29)
Nevada (148)
New Hampshire (89)
New Jersey (3686)
New Mexico (33)
New York (3666)
North Carolina (1852)
North Dakota (11)
Northern California (6976)
Ohio (425)
Oklahoma (25)
Oregon (47)
Pennsylvania (2769)
Puerto Rico (30)
Rhode Island (52)
South America (1375)
South Carolina (87)
South Dakota (2)
Southern California (5483)
Tennessee (221)
Texas (2225)
United States (49567)
Utah (417)
Vermont (1)
Virginia (351)
Washington D.C. (87)
Washington State (1130)
West Virginia (4)
Wisconsin (150)
Wyoming (2)
802,340 Results for "s1 biopharma formerly known as s1 pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Lung cancer
Merck’s early PD-1/VEGF data competitive in lung cancer, but Summit ‘looms large’
While Merck’s PD-1/VEGF asset appears to match the performance of Summit Therapeutics’ ivonescimab, the pharma’s Phase 1/2 readout in non-small cell lung cancer still leaves analysts with some questions moving into later-stage development.
April 20, 2026
·
2 min read
·
Tristan Manalac
Immuno-oncology
Summit’s PD-1/VEGF to take center stage at ASCO, with wide impact for peers
As Summit Therapeutics’ Chinese partner prepares to reveal data for a key trial at ASCO, analysts consider the impact on rivals Merck, Bristol Myers Squibb and BioNTech.
May 29, 2026
·
4 min read
·
Annalee Armstrong
Drug Development
4 troubled targets that have thwarted biopharma
The tragic tale of TIGIT is well known. However, RIPK1, myc, STING and alpha-synuclein have also left a trail of failed clinical trials, canceled partnerships and sunk investments in their wake.
May 26, 2026
·
9 min read
·
Tristan Manalac
Press Releases
FluoGuide A/S Publishes Interim Report for Q1 2026
May 27, 2026
·
4 min read
Earnings
Keytruda Hangs On to Best Seller Crown as GLP-1s Gain Ground
Merck’s Keytruda will soon lose exclusivity, just as weight-loss giants Eli Lilly and Novo Nordisk press in with their blockbuster GLP-1s.
March 4, 2026
·
9 min read
·
Tristan Manalac
Press Releases
Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split Ratio
May 7, 2026
·
4 min read
Alzheimer’s disease
In Novo’s GLP-1 Failure, Alzheimer’s Space Spies a Combination Opportunity
Despite the definitive failure of Novo Nordisk’s semaglutide in Alzheimer’s, biotech executives, analysts and other industry experts see potential in more testing of GLP-1s for the neurodegenerative disease, particularly in a combination approach.
January 2, 2026
·
5 min read
·
Annalee Armstrong
Job Trends
Biopharmas pull back on layoffs in Q1
The trend of fewer companies letting employees go, which began in the fourth quarter of last year, has continued. However, more employees were on the chopping block in Q1 2026 than in Q1 2025, due mainly to one company’s cuts.
April 16, 2026
·
4 min read
·
Angela Gabriel
Press Releases
Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)
May 27, 2026
·
13 min read
Sponsored
What Biopharma Can Learn from Formula 1: Precision, Speed, and the Power of the Right Partner
As the Formula 1 season kicks off in the APAC region, biopharma companies can take a page from the popular sport’s playbook around precision, adaptability, and the right team. In return, biopharma can also offer some lessons to elite motor sport on well-rounded excellence in the race to market.
March 16, 2026
·
5 min read
1 of 80,234
Next
